Terkko Navigator / Alimentary Pharmacology & Therapeutics

Chronic opioid use is associated with early biologic discontinuation in inflammatory bowel disease

Applications of machine learning models in the prediction of gastric cancer risk in patients after Helicobacter pylori eradication

Cross‐linkage between bacterial taxonomy and gene functions: a study of metagenome‐assembled genomes of Gut Microbiota in adult non‐alcoholic fatty liver disease

Editorial: immune‐mediated diseases—are we closer to disease‐defining molecular signatures?

Addition of liver stiffness enhances the predictive accuracy of the PAGE‐B model for hepatitis B‐related hepatocellular carcinoma

Serum hepatitis B core‐related antigen level stratifies risk of disease progression in chronic hepatitis B patients with intermediate viral load

Incremental value of HBcrAg to classify 1582 HBeAg‐negative individuals in chronic infection without liver disease or hepatitis

Similar 5‐year HCC occurrence in Tenofovir‐ and Entecavir‐treated HBV chronic infection in the French AFEF/ANRS CO22 Hepather cohort

Randomised clinical trial: exclusive enteral nutrition versus standard of care for acute severe ulcerative colitis

An expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials

Outcomes of upper gastrointestinal bleeding are similar between direct oral anticoagulants and vitamin K antagonists

Transmural healing and MRI healing are associated with lower risk of bowel damage progression than endoscopic mucosal healing in Crohn’s disease

Impact of proton pump inhibitors on cytochrome P450 activity assessed by 13C‐aminopyrine breath test in patients with cirrhosis

Drug survival of anti‐TNF agents compared with vedolizumab as a second‐line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers

AP&T: Editors’ Declarations of Interest

A Message from the Editors

Hyperbaric oxygen therapy for the treatment of perianal fistulas in 20 patients with Crohn’s disease

The diagnostic and prognostic significance of liver histology in alcoholic hepatitis

Fructan‐sensitive children with irritable bowel syndrome have distinct gut microbiome signatures

Systematic review with meta‐analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre‐existing inflammatory bowel diseases

Targeted versus universal tuberculosis chemoprophylaxis in 1968 patients with inflammatory bowel disease receiving anti‐TNF therapy in a tuberculosis endemic region

Non‐selective beta‐blocker use in cirrhotic patients is associated with a reduced likelihood of hospitalisation for infection

Effectiveness and safety of obeticholic acid in a Southern European multicenter cohort of patients with primary biliary cholangitis and suboptimal response to ursodeoxycholic acid

Carvedilol is associated with improved survival in patients with cirrhosis: a long‐term follow‐up study

Confounding and bias in observational studies in inflammatory bowel disease: a meta‐epidemiological study

Review article: Elobixibat: a novel treatment for chronic constipation

Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study

Immune‐mediated diseases and risk of Crohn’s disease or ulcerative colitis: a prospective cohort study

Phenome‐wide association study in adult coeliac disease: role of HLA subtype

Derivation and validation of a novel method to subgroup patients with functional dyspepsia: beyond upper gastrointestinal symptoms

Mucosal penetration and clearance of gluten and milk antigens in eosinophilic oesophagitis

Microbiome as a potential diagnostic and predictive biomarker in severe alcoholic hepatitis

Colectomy rates for ulcerative colitis in England 2003‐2016

Randomised clinical trial: safety, efficacy and pharmacokinetics of HS‐10234 versus tenofovir for the treatment of chronic hepatitis B infection

Systematic review with meta‐analysis: the effects of immunomodulator or biological withdrawal from mono‐ or combination therapy in inflammatory bowel disease

Circulatory microRNAs as potential biomarkers for fatty liver disease: the Rotterdam study

Impact of abdominal or pelvic radiotherapy on disease activity in inflammatory bowel disease: a multicentre cohort study from the AID

Validating the positivity thresholds of drug‐tolerant anti‐infliximab and anti‐adalimumab antibody assays

Review article: current gaps and opportunities in HBV prevention, testing and linkage to care in the United States—a call for action

Similarly low risk of hepatocellular carcinoma after either spontaneous or nucleos(t)ide analogue‐induced hepatitis B surface antigen loss

Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss

Serum triiodothyronine‐to‐thyroxine (T3/T4) ratio predicts therapeutic outcome to biological therapies in elderly IBD patients

Upper gastrointestinal bleeding in Scotland 2000‐2015: trends in demographics, aetiology and outcomes

Review article: exposure to microbes and risk of coeliac disease

Randomised clinical trial: high‐dose oral thiamine versus placebo for chronic fatigue in patients with quiescent inflammatory bowel disease

Vedolizumab treatment persistence and safety in a 2‐year data analysis of an extended access programme

Letter: faecal microbiota transplantation for irritable bowel syndrome—which improvements are required? Authors' reply

Letter: elevated aspartate aminotransferase and aspartate aminotransferase to alanine aminotransferase ratio predicts poor survival in hepatocellular carcinoma after resection

Letter: the use of Fibrosis‐4 score in primary care and diabetology practices—Occam's razor applied to advanced fibrosis screening. Authors' reply

Letter: synergistic role of gut flora with aspirin to prevent colorectal cancers